AUTHOR=Chieng Wei Keong , Abdul Jalal Muhammad Irfan , Bedi Jashveerdeep Singh , Zainuddin Ani Amelia , Mokhtar Mohd Helmy , Abu Muhammad Azrai , Chew Kah Teik , Nur Azurah Abdul Ghani 

TITLE=Probiotics, a promising therapy to reduce the recurrence of bacterial vaginosis in women? a systematic review and meta-analysis of randomized controlled trials

JOURNAL=Frontiers in Nutrition

VOLUME=9

YEAR=2022

URL=https://www.frontiersin.org/journals/nutrition/articles/10.3389/fnut.2022.938838

DOI=10.3389/fnut.2022.938838

ISSN=2296-861X

ABSTRACT=<sec><title>Introduction</title><p>The evidence for probiotic efficacy in preventing bacterial vaginosis (BV) recurrences among women aged 18 years and above is sparse. We aimed to ascertain the efficacy of probiotics in preventing BV recurrences after at least one menstrual cycle in this population.</p></sec><sec><title>Methods</title><p>We conducted a systematic literature search using PubMed, MEDLINE (Ovid interface), Web of Science (WoS), Scopus, Embase, ProQuest Dissertations and Theses Global, Cochrane Library databases and registries comprised of Open Science Framework (OSF) preprints registry, the <ext-link ext-link-type="uri" xlink:href="https://clinicaltrials.gov" xmlns:xlink="http://www.w3.org/1999/xlink">ClinicalTrials.gov</ext-link> (USA), WHO International Clinical Trials Registry Platform (WHO-ICTRP), International Standard RCT Number (ISRCTN) registry, limited to randomized clinical trials (RCTs) in English published between January 2000 and December 2021. The inclusion criteria were trials that administered probiotics to BV-positive women in an experimental arm of at least 20 samples. The usage of probiotics should be preceded with standard antibiotic regimen and followed by a reassessment of BV status after at least a single menstrual cycle. Risk of bias assessment was completed using revised Cochrane risk-of-bias tool for randomized trials (RoB 2). The PROSPERO registration number of the review is CRD42022302044.</p></sec><sec><title>Results</title><p>From 8,162 identified records, we included 10 studies (<italic>n</italic> = 1,234 participants) for final analysis; 7 trials compared probiotics vs. placebo, whereas 3 trials compared probiotics vs. metronidazole alone. Using random-effects meta-analysis, probiotics were shown to reduce the risk of BV recurrences by 45% compared to either placebo or metronidazole [14.8 vs. 25.5%, RR: 0.55 (95%CI: 0.33, 0.91), <italic>p</italic> = 0.03, <italic>I</italic><sup>2</sup> = 45.4% (95%CI: 0, 73.7%)]. Sensitivity analysis revealed the robustness of results upon removal of studies with high risk of bias [RR: 0.54 (95%CI: 0.38, 0.77), <italic>p</italic> = 0.006] and reporting bias (RR: 0.53, 95%CI: 0.39, 0.74, <italic>p</italic> = 0.002). Meta-regression demonstrated that the route of administration (<italic>p</italic><sub>vaginal</sub> = 0.67; <italic>p</italic><sub>oral</sub> = 0.44), the total dosage of probiotics (<italic>p</italic> = 0.17), cumulative days of probiotic administration (<italic>p</italic> = 0.76), and the number of species in probiotic preparation (<italic>p</italic> = 0.40) were not linked to BV recurrences.</p></sec><sec><title>Interpretation</title><p>Probiotics were associated with more than twofold reduction in BV recurrences when BV status was assessed after at least 1-month postintervention. Further high-quality and methodologically standardized RCTs should evaluate probiotic efficacy for BV prevention in a diverse community setting.</p></sec><sec><title>Systematic review registration</title><p>[<ext-link ext-link-type="uri" xlink:href="https://www.crd.york.ac.uk/prospero/display_record.php?ID=CRD42021290613" xmlns:xlink="http://www.w3.org/1999/xlink">https://www.crd.york.ac.uk/prospero/display_record.php?ID=CRD42021290613</ext-link>], identifier [CRD42021290613].</p></sec>